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Summary
Background—Low plasma 25-hydroxyvitamin D (25[OH]D) concentration is associated with 
high arterial blood pressure and hypertension risk, but whether this association is causal is 
unknown. We used a mendelian randomisation approach to test whether 25(OH)D concentration is 
causally associated with blood pressure and hypertension risk.
Methods—In this mendelian randomisation study, we generated an allele score (25[OH]D 
synthesis score) based on variants of genes that affect 25(OH)D synthesis or substrate availability 
(CYP2R1 and DHCR7), which we used as a proxy for 25(OH)D concentration. We meta-analysed 
data for up to 108 173 individuals from 35 studies in the D-CarDia collaboration to investigate 
associations between the allele score and blood pressure measurements. We complemented these 
analyses with previously published summary statistics from the International Consortium on 
Blood Pressure (ICBP), the Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) consortium, and the Global Blood Pressure Genetics (Global BPGen) consortium.
Findings—In phenotypic analyses (up to n=49 363), increased 25(OH)D concentration was 
associated with decreased systolic blood pressure (β per 10% increase, −0·12 mm Hg, 95% CI 
−0·20 to −0·04; p=0·003) and reduced odds of hypertension (odds ratio [OR] 0·98, 95% CI 
0·97−0·99; p=0·0003), but not with decreased diastolic blood pressure (β per 10% increase, −0·02 
mm Hg, −0·08 to 0·03; p=0·37). In meta-analyses in which we combined data from D-CarDia and 
the ICBP (n=146 581, after exclusion of overlapping studies), each 25(OH)D-increasing allele of 
the synthesis score was associated with a change of −0·10 mm Hg in systolic blood pressure 
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(−0·21 to −0·0001; p=0·0498) and a change of −0·08 mm Hg in diastolic blood pressure (−0·15 to 
−0·02; p=0·01). When D-CarDia and consortia data for hypertension were meta-analysed together 
(n=142 255), the synthesis score was associated with a reduced odds of hypertension (OR per 
allele, 0·98, 0·96−0·99; p=0·001). In instrumental variable analysis, each 10% increase in 
genetically instrumented 25(OH)D concentration was associated with a change of −0·29 mm Hg in 
diastolic blood pressure (−0·52 to −0·07; p=0·01), a change of −0·37 mm Hg in systolic blood 
pressure (−0·73 to 0·003; p=0·052), and an 8·1% decreased odds of hypertension (OR 0·92, 0·87–
0·97; p=0·002).
Interpretation—Increased plasma concentrations of 25(OH)D might reduce the risk of 
hypertension. This finding warrants further investigation in an independent, similarly powered 
study.
Introduction
Low vitamin D status has been associated with an increased risk of cardiovascular disease 
and all-cause mortality, and the possible benefits of vitamin D supplementation are being 
actively investigated and debated.1,2 In observational studies, low plasma 25-
hydroxyvitamin D (calcidiol, 25[OH]D) concentration is associated with an increased risk of 
hypertension.3 However, few large randomised controlled trials of vitamin D 
supplementation with primary cardiovascular outcomes have been done, and secondary 
analyses from other trials have provided little evidence to support an effect of vitamin D 
supplementation on cardiovascular outcomes.1,4,5 The largest of the randomised controlled 
studies was the Women’s Health Initiative trial4 (n=36 282), the results of which did not 
show any changes in blood pressure or hypertension after 7 years of follow-up.4 However, 
the vitamin D dose used in that trial was quite small (400 IU per day), and women in both 
treatment and placebo groups were allowed to take up to 1000 IU per day of additional 
open-label vitamin D supplementation. Some evidence for possible effects of vitamin D 
supplementation on blood pressure has been obtained from randomised controlled trials with 
higher doses6 and those investigating individuals with cardio-metabolic risk;5 however, as 
Elamin and colleagues have previously noted,7 the quality of the available evidence is “low 
to moderate at best”.
In this study, we explored the possible causal relation between vitamin D status and blood 
pressure and hypertension using a genetic approach. Mendelian randomisation exploits the 
fact that individual genotypes are assigned randomly at meiosis, so the effect of genetics on 
disease is generally unaffected by confounding or reverse causality.8 Recent genome-wide 
association studies (GWAS) have identified several variants that affect circulating 
concentrations of 25(OH)D.9 If 25(OH)D concentrations are causally involved in 
determining blood pressure or the risk of hypertension, then the genetic variants that affect 
circulating concentrations of 25(OH)D could be expected to affect blood pressure and 
hypertension risk. This assumption seems to be valid for at least two of the genes that affect 
25(OH)D, namely CYP2R1 (encoding cytochrome P450, family 2, subfamily R, polypeptide 
1) and DHCR7 (encoding 7-dehydrocholesterol reductase). These genes function upstream 
of 25(OH)D production and affect vitamin D synthesis or substrate availability.10,11 Two 
further downstream variants affect 25(OH)D, GC (encoding group-specific component 
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[vitamin D binding protein]) and CYP24A1 (encoding cytochrome P450, family 24, 
subfamily A, polypeptide 1), but both are known to have pleiotropic effects.12,13 In this 
study, we used genetic variants that affect vitamin D synthesis as proxy markers for lifelong 
differences in vitamin D status to test for a causal association with blood pressure and 
hypertension.
Methods
Study design and population
We used a mendelian randomisation approach to investigate the association between genetic 
variants that affect concentrations of circulating 25(OH)D and blood pressure 
measurements. We meta-analysed data from 35 studies in the D-CarDia collaboration, with 
results complemented by previously published summary statistics from other large-scale 
consortium efforts.14–16 D-CarDia is a collaboration of studies, consisting of cohorts of 
European ancestry from Europe and North America, that investigates the association of 
vitamin D and the risk of cardiovascular disease and related traits.11 We meta-analysed 
directly genotyped and imputed single-nucleotide polymorphisms (SNPs) from 31 adult 
(aged 31–92 years, n=99 582) and four adolescent (aged 10–20 years, n=8591) cohorts in 
the D-CarDia collaboration (table 1, figure 1). All participants provided written informed 
consent, and all participating studies received approval from local research ethics 
committees. The appendix (pp 2–19) includes descriptions of all the studies included in the 
analysis.
To further increase the statistical power of our study, we meta-analysed our results in adults 
with data from the International Consortium for Blood Pressure (ICBP)14 when examining 
systolic or diastolic blood pressure as the outcome (n=146 581, after exclusion of 
overlapping studies; figure 1). At the time of the study, hypertension had not been formally 
examined as an outcome in the ICBP consortium, and related coefficients were not 
available. Therefore, we used summary data from Cohorts for Heart and Aging Research in 
Genomic Epidemiology (CHARGE; n=29 136)16 and Global Blood Pressure Genetics 
(Global BPGen) (n=34 433)15 consortia when examining hypertension as the outcome 
(n=142 255 after exclusion of overlapping studies; figure 1).
Phenotypic measures
Hypertension was defined as systolic blood pressure of 140 mm Hg or higher, diastolic 
blood pressure of 90 mm Hg or higher, or current use of antihypertensive drugs. For 
participants taking antihypertensive drugs, we added 15 mm Hg to systolic and 10 mm Hg to 
diastolic blood pressure to correct for the effect of the treatment.14
25(OH)D concentrations were available for 19 of the 35 studies in the D-CarDia 
collaboration (n=51 122), with values expressed in nmol/L for all studies. The appendix (pp 
2–19) includes details about the methods used to measure 25(OH)D concentration in each 
study.
Vimaleswaran et al. Page 3
Lancet Diabetes Endocrinol. Author manuscript; available in PMC 2015 September 25.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Selection of SNPs and allele scores
To create vitamin D allele scores, we selected four vitamin D-related SNPs (DHCR7 
rs12785878, CYP2R1 rs12794714, GC rs2282679, and CYP24A1 rs6013897) based on the 
results of the GWAS by the SUNLIGHT Consortium,9 with two SNPs in genes located 
upstream (DHCR7 and CYP2R1) and two downstream (GC and CYP24A1) of the 25(OH)D 
metabolite.10 All but one (CYP2R1) were selected as the top hit; for CYP2R1 we used an 
alternative SNP also identified by the GWAS by the SUNLIGHT Consortium (p=1·84 × 
10−9 for association with 25[OH]D concentration) because it was a functional variant in 
moderate linkage disequilibrium (r2=0·41) with the first-stage GWAS top hit rs10741657.9 
The appendix (pp 2–25) includes a detailed description of the genotyping and imputation 
methods and effect allele frequencies for all the studies included in the meta-analysis.
We created two separate vitamin D allele scores: a synthesis allele score, created by 
summing the vitamin D-increasing alleles in the genes located upstream (DHCR7 and 
CYP2R1; score range 0–4), and a metabolism allele score, created by summing the vitamin 
D-increasing alleles in the genes located downstream (GC and CYP24A1; score range 0–4) 
of the 25(OH)D metabolite.10,11 The synthesis allele score can be regarded as an instrument 
for 25(OH)D concentration when testing for causal association in mendelian randomisation 
analyses because it consists of variants that directly affect substrate availability or synthesis 
of 25(OH)D. Components included in the metabolism score are relevant for the transfer and 
clearance of 25(OH)D and could provide insights into the effect of vitamin D metabolism on 
blood pressure. However, the use of the metabolism score as a formal instrument in 
mendelian randomisation analyses is not possible because of problems with quantification of 
expected associations, pleiotropic effects,12,13 and the metabolic feedback loops associated 
with the clearance of vitamin D-related metabolites by CYP24A1.17 Investigations with the 
vitamin D metabolism score were therefore exploratory only.
Statistical analysis
Statistical analyses in each of the D-CarDia studies were done in accordance with a standard 
analysis plan. We used the natural-log transformation for 25(OH)D concentrations to 
achieve a closer approximation of the normal distribution, and to remove non-linearity in the 
association with the outcomes. Additive models with systolic blood pressure, diastolic blood 
pressure, and hypertension as outcomes were adjusted for age, age-squared, BMI, sex, 
geographical region, or principal components (as relevant for the study); models with 
25(OH)D concentration as the outcome were additionally adjusted for month of blood 
sample collection and laboratory batch, as relevant.
With respect to the phenotypic analyses, confounding factors that affect 25(OH)D 
concentrations were assessed previously with the 1958 British birth cohort10 and in selected 
D-CarDia studies with individual-level data (appendix pp 26–28). To assess the association 
of 25(OH)D concentration with systolic blood pressure, diastolic blood pressure, and 
hypertension, the investigators of each of the D-CarDia studies did linear regression 
analyses, adjusting for the key covariates as adjusted for in the additive models, and the 
models were repeated stratified by sex (appendix p 39).
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With respect to genetic effects on 25(OH)D concentration, the effect allele was the 
25(OH)D-increasing allele, as established by the SUNLIGHT Consortium.9 We tested the 
association of the four individual vitamin D-related genetic markers, and the two vitamin D 
allele scores, with 25(OH)D concentrations using linear regression models, adjusting for the 
same covariates as adjusted for in the additive models. We tested for associations of the 
synthesis score, and its components, with several confounders: age, sex, season, BMI, total 
cholesterol, and triglycerides (appendix pp 29–32). To examine variations that could affect 
the validity of the instruments, we used meta-regression to assess heterogeneity in the 
associations between the SNPs and 25(OH)D concentration by study-level factors: sex, age, 
method of blood pressure measurement (manual, automated, or random-zero manometer), 
proportion of hypertensive participants, geographical region (UK, central and southern 
Europe, North America, Scandinavia, or Finland), and BMI. Models were repeated with 
adjustment for serum triglycerides and total cholesterol (to exclude pleiotropic effects 
through lipid metabolism, since 25[OH]D is a cholesterol derivative) in addition to the the 
covariates as adjusted for in the additive models when examining systolic blood pressure, 
diastolic blood pressure, and hypertension as outcomes.
To examine the strength of the synthesis allele score as an instrument, we calculated the F-
statistic from the proportion of variation in the respective phenotype (R2) explained by the 
allele score (F-statistic=(R2×(n–2))/(1–R2)].18 We used the inverse of the F-statistic to 
calculate the relative bias of the instrumental variable ratio compared with ordinary least-
squares linear regression.19 Because external weights were not available and the use of 
internal weights could bias the instrumental variable results, we did an unweighted allele 
score analysis for the vitamin D SNPs (appendix p 39).
We did the formal mendelian randomisation analyses to estimate the possible causal 
relationship between 25(OH)D concentration and systolic blood pressure, diastolic blood 
pressure, and hypertension using the instrumental variable ratio method.20 To estimate the 
instrumental variable ratio for the effect of 25(OH)D concentration on systolic blood 
pressure, diastolic blood pressure, and hypertension, we divided the meta-analysed 
association of the vitamin D synthesis allele score with systolic blood pressure, diastolic 
blood pressure, and hypertension by the association of vitamin D synthesis allele score with 
25(OH)D concentration. We estimated the variance for the instrumental variable ratio using 
a Taylor expansion.21
We used summary statistics for the four vitamin D SNPs from the ICBP,14 Global BPGen15 
and CHARGE16 consortia to increase the statistical power of our analyses of the association 
between the vitamin D allele scores and blood pressure outcomes. We used an 
approximation method that has been previously described14 to combine SNPs into the 
synthesis and metabolism allele scores.
In the presence of heterogeneity of association between the studies, we used random-effects 
meta-analyses; otherwise, we tested fixed-effects models. We investigated sources of 
heterogeneity with univariate meta-regression models.
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Four studies in the D-CarDia collaboration are in adolescents (aged 10–20 years, n=8591). 
The main meta-analyses were restricted to adult populations (aged 31–92 years, n=99 582), 
and only exploratory analyses were done in adolescents because of insufficient sample sizes 
(appendix pp 20, 33, and 39).
We did additional sensitivity analyses to examine the effect of adjusting for lipids (appendix 
p 34) of the quality of genetic information (appendix p 35), and of the adjustment applied for 
the use of antihypertensive drugs (appendix p 36), as well as to compare the two-stage 
instrumental variable ratio method with the meta-analysis of study-specific instrumental 
variable ratios (appendix p 37).
All meta-analyses were done at the UCL Institute of Child Health (University College 
London, London, UK) with Stata version 12.
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to summary 
data from all studies and had final responsibility for the decision to submit for publication.
Results
All four vitamin D-related SNPs were strongly associated with 25(OH)D concentrations 
(p<2·22 × 10−12 for all comparisons; appendix p 33). As previously reported,10,11 the 
synthesis and metabolism allele scores were strongly associated with 25(OH)D 
concentrations (synthesis score β 2·83%, 95% CI 2·48–3·18, p=2·70 × 10−55, R2=0·5%; 
metabolism score β 5·38%, 4·67–6·08, p=5·93 × 10−50, R2=1·4%; appendix p 33). There was 
no evidence for heterogeneity in the association between the synthesis score and 25(OH)D 
concentration (I2=0%, p=0·48). Heterogeneity was seen for the metabolism score (I2=57%, 
p=0·003), with evidence of variation in the association between metabolism score and 
25(OH)D concentration by mean study BMI (p=0·02). The F-statistic for the synthesis allele 
score was 219·7, which suggests a strong composite instrument. The relative bias of the 
instrumental variable ratio compared with ordinary least-square linear regression was small 
(0·5%).
Increased 25(OH)D concentrations were associated with reduced systolic blood pressure (β 
per 10% change, −0·12 mm Hg, 95% CI −0·20 to −0·04; p=0·003) and reduced odds of 
hypertension (odds ratio [OR] 0·98, 95% CI 0·97–0·99; p=0·0003); however, we did not see 
an association between 25(OH)D concentration and diastolic blood pressure (β −0·02 mm 
Hg, −0·08 to 0·03; p=0·37; appendix p 40). Despite evidence for heterogeneity in the 
phenotypic association between 25(OH)D concentration and the outcomes within the studies 
done in adults (systolic blood pressure, I2=73%, p=9·19×10−07; diastolic blood pressure, 
I2=78%, p=5·00×10−09; hypertension, I2=62%, p=0·001), the observed association between 
25(OH)D concentration and systolic blood pressure, diastolic blood pressure, or 
hypertension between studies did not vary by age (meta-regression p≥0·09 for all 
comparisons), sex (meta-regression p≥0·65), method of blood pressure measurement (meta-
regression p≥0·14), geographical region (meta-regression p≥0·39), or BMI (meta-regression 
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p≥0·10). However, for the association between 25(OH)D concentration and diastolic blood 
pressure, there was variation across the proportion of hypertensive participants (meta-
regression p=0·01).
In the meta-analyses of the D-CarDia studies (n=108 173), there was no association of the 
synthesis allele score with systolic blood pressure (β per 25[OH]D-increasing allele, −0·10 
mm Hg, 95% CI −0·23 to 0·02; p=0·11), diastolic blood pressure (β −0·07 mm Hg, −0·15 to 
0·01; p=0·07), or hypertension (OR 0·99, 95% CI 0·97–1·00; p=0·08). After increasing the 
sample size by meta-analysing the D-CarDia results with the summary data from the ICBP 
consortium (total n=146 581, after exclusion of overlapping studies), the precision of 
estimation was improved, but the estimated strengths of these associations remained 
unchanged. The synthesis score was associated with both systolic blood pressure (β −0·10 
mm Hg, −0·21 to −0·0001; p=0·0498) and diastolic blood pressure (β −0·08 mm Hg, −0·15 
to −0·02; p=0·01; figure 2). For hypertension as the outcome, we meta-analysed the 
summary results from the CHARGE and Global BPGen consortia with the study results 
from adults in the D-CarDia collaboration (total n=142 255, after exclusion of overlapping 
studies). This analysis showed that the synthesis score was associated with hypertension 
(OR for increase per allele, 0·98, 0·96–0·99; p=0·001; figure 2). The metabolism allele score 
was not associated with any blood pressure outcomes. For analyses with maximum samples 
sizes, β for systolic blood pressure was −0·001 mm Hg (95% CI −0·12 to 0·12; p=0·99), β 
for diastolic blood pressure was 0·005 mm Hg (−0·07 to 0·08; p=0·90), and the OR for 
hypertension was 0·99 (0·98–1·01; p=0·48; appendix p 44).
In the instrumental variable analysis, in which the synthesis score was used as an instrument, 
the direction of association between 25(OH)D concentration and all outcomes was 
compatible with that suggested by the observational phenotypic associations (table 2). Every 
10% relative increment in genetically instrumented 25(OH)D concentration was associated 
with 0·29 mm Hg lower diastolic blood pressure (95% CI 0·07 to 0·52; p=0·01) and a 0·37 
mm Hg lower systolic blood pressure (−0·003 to 0·73; p=0·052). Every 10% increment in 
25(OH)D concentration was associated with an 8·1% reduced odds of hypertension (OR 
0·92, 95% CI 0·87–0·97; p=0·002) in the instrumental variable ratio analyses (table 2, figure 
3).
The CYP2R1 SNP was individually associated with reduced diastolic blood pressure (per 
allele, β −0·09 mm Hg, 95% CI −0·18 to −0·01; p=0·03) and reduced odds of hypertension 
(OR for increase per allele, 0·98, 0·96–1·00; p=0·02), but no individual associations were 
seen for the DHCR7 SNP, or either of the downstream metabolism SNPs (GC and 
CYP24A1), with any of the blood pressure outcomes (appendix pp 41–43).
Discussion
The results of our mendelian randomisation analysis provide evidence for a causal effect of 
low vitamin D status on increasing blood pressure and risk of hypertension. This finding 
lends support to continued efforts to prevent vitamin D deficiency. In view of the costs and 
side-effects associated with antihypertensive drugs, the potential to reduce hypertension by 
vitamin D is very attractive. However, because we cannot exclude the possibility that our 
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findings were caused by chance, they need to be replicated in an independent, similarly 
powered study.
Evidence from randomised controlled trials to assess the effectiveness of vitamin D 
supplementation in reducing blood pressure have not provided consistent evidence of a 
benefit.1 In subgroup analyses done within meta-analyses of these trials,5,22 some reductions 
in diastolic blood pressure were reported for participants with hypertension or 
cardiometabolic disease, and when studies that used higher doses were compared with those 
that used lower doses of vitamin D.23 Although the investigators of one study6 reported 
dose-dependent reductions in systolic blood pressure after 3 months of supplementation with 
1000 IU, 2000 IU, and 4000 IU of vitamin D per day (0·66, 3·4, and 4·0 mm Hg, 
respectively), no effect was seen in another trial24 in which participants were given a bolus 
supplement of 100 000 IU every 3 months. These inconsistencies could be attributed to 
differences in the mode of administration, dose, and duration of supplementation, or to 
baseline differences in 25(OH)D concentrations or blood pressure, or other sources of 
heterogeneity between the studies. Thus, the evidence remains inconclusive. Nevertheless, 
these exploratory randomised controlled trials have paved the way for large trials (with 
upwards of 18 000 participants) that are being undertaken to examine the benefits of vitamin 
D for the prevention of cardiovascular disease outcomes.25
Our findings are biologically plausible. Inappropriate activation of the renin-angiotensin 
system increases blood pressure and the risk of cardiovascular disease.26 Studies in animals 
have shown that 1,25-dihydroxy-vitamin D (calcitriol, 1,25[OH] 2D) suppresses the 
expression of the renin gene by a vitamin D receptor-dependent mechanism, thereby 
lowering blood pressure.27 In an open-label, blinded-endpoint trial28 in 101 patients with 
chronic heart failure who were randomly assigned to receive 2000 IU of oral vitamin D3 per 
day for 6 weeks or control (no treatment), treatment led to a significant decrease in plasma 
renin activity (p=0·002) and concentration (p=0·02). However, some findings have raised 
concerns about whether activation of the renin-angiotensin system has a role in the vitamin 
D-deficient state in human beings.29 Vitamin D metabolites could also exert 
antihypertensive effects through various other molecular mechanisms. Vitamin D is 
indirectly related to blood pressure through its regulation of calcium absorption from the gut 
and its interaction with parathyroid hormone in the maintenance of calcium homeostasis. 
The reno-protective and anti-inflammatory actions of vitamin D metabolites and their 
analogues suggest a possible role for vitamin D deficiency in cardiovascular morbidity and 
mortality in patients with chronic kidney disease.30 Furthermore, adipocyte inflammation 
has a crucial role in hypertension: in an in-vitro study,31 1,25(OH)2D inhibited 
lipopolysaccharide-stimulated cytokine secretion in two human adipocyte models through 
direct inhibition of nuclear factor-κB.
On the basis of our effect size estimates, the genetic associations of the synthesis allele score 
with systolic or diastolic blood pressure were less pronounced than that seen for 
hypertension (represented as a binary trait). This finding might suggest that adequate 
25(OH)D concentrations are particularly important for the prevention of hypertension as a 
clinical outcome. This interpretation is also supported by the results of sensitivity analyses 
in normotensive individuals, which showed that both the phenotypic association and the 
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genetically indexed association between 25(OH)D concentrations and blood pressure were 
substantially weaker in this subgroup than in the full sample (data not shown).
Although the mendelian randomisation approach is helpful in testing for underlying 
causality,20 an imbalance in the possible overestimation or underestimation of the genetic 
associations for the outcome and exposure could affect the quantification of the effect.32 The 
weaker association with blood pressure than with hypertension could also reflect a greater 
measurement error or heterogeneity in the assessment of gradual increases across the range 
of the blood pressure distribution, compared with the classification of hypertension by raised 
blood pressure or use of antihypertensive drugs. Such noise or heterogeneity in the blood 
pressure measurements in our meta-analyses could also account for why the estimated 
strength of the associations between 25(OH)D concentrations and blood pressure outcomes 
were weaker than we would have expected on the basis of previous observational analyses 
or of power calculations that were done with data from one of the D-CarDia studies (1958 
British birth cohort, n=6877).10
The main strength of our study is in the large sample size (up to n=146 581), which allowed 
us to assess the consistency of associations across several studies and to gain sufficient 
power for conclusive analyses. This study shows the benefits of the mendelian 
randomisation approach: although the phenotypic associations between 25(OH)D 
concentrations and blood pressure or hypertension were very heterogeneous across the 
studies, notably less heterogeneity was seen for the genetic associations. Age and adiposity 
are issues that would be expected to affect 25(OH)D concentrations and bias the phenotypic 
association it might have with blood pressure, but participating studies included both young 
and old cohorts, and both lean and obese participants. By contrast, genetic variants used in 
mendelian randomisation would be expected to reflect lifelong differences in 25(OH)D 
concentrations and would therefore be less affected by temporal variations in individual 
characteristics.
Potential limitations with the mendelian randomisation approach include the requirement of 
large sample sizes, the possibility of population stratification, canalisation, pleiotropy, and 
an inability to generalise findings to people in other ethnic groups. A limitation of our study 
was that we only looked at associations with blood pressure and hypertension, and whether 
these associations are related to differences in the risks of rarer disease outcomes remains 
uncertain. Population stratification is unlikely to have had a major effect on our main 
findings, since participants were all of European descent, and we adjusted for geographical 
region and principal components from the population stratification analysis in the statistical 
models.
The synthesis or metabolism SNPs might have led to biological adaptations during 
development (ie, canalisation),8 although this possibility seems unlikely in view of the 
similar associations with 25(OH)D seen in the analyses done in adolescents and adults. 
Pleiotropic effects, wherein the genetic instruments might affect other metabolic pathways 
independent of their influence on 25(OH)D concentration, are more likely. Our main 
instrument was a composite score consisting of two independent SNPs. Although 
differential associations between the components included in the score can suggest a 
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possible pleiotropic effect, in our case the associations for CYP2R1 and DHCR7 were 
similar for all three outcomes (appendix p 38). Furthermore, because 25(OH)D is a 
secosteroid, we explicitly sought to exclude pleiotropic effects through lipid metabolism by 
adjusting for serum triglycerides and total cholesterol in addition to other covariates, and 
noted no differences in our findings (appendix p 34). However, pleiotropy is an issue with 
the metabolism variants included in our secondary analyses. The GC allele that is associated 
with increased 25(OH)D concentrations also leads to reduced bioavailability of active 
1,25(OH)2D,12 hence increased serum concentrations of the 25(OH)D substrate are a 
possible consequence of reduced uptake by the cells. CYP24A1 in turn acts as a hydroxylase 
for other vitamin D metabolites in addition to 25(OH)D, and the activity of the enzyme 
probably reflects the absolute 25(OH)D concentration, raising uncertainty about the 
association we would expect to see with the outcome. Indeed, we noted no evidence for 
associations between the metabolism SNPs and the blood pressure outcomes.
Panel: Research in context
Systematic review
Investigators of several systematic reviews1,5,7,23 have summarised evidence for the 
phenotypic association between 25-hydroxyvitamin D (25[OH]D) and blood pressure and 
assessed the cardiovascular effects of vitamin D supplementation in randomised 
controlled trials. A prospective phenotypic association is well established, but few large 
randomised controlled trials of vitamin D with primary cardiovascular outcomes have 
been done. Evidence is largely restricted to secondary analyses of mostly small trials that 
were initially established to assess the effects of vitamin D supplementation on bone 
health. Some effects have been reported from subgroup analyses of trials focused on 
individuals with cardiometabolic disease,5,22 but the quality of the available evidence has 
been criticised.7 Previous studies that have used mendelian randomisation analyses to 
examine the association of 25(OH)D and cardiovascular outcomes have been 
underpowered and evidence for causality of association is inconclusive.22,33
Interpretation
Our results suggest that people who have genetic variants associated with low 
endogenous production of 25(OH)D have an increased risk of hypertension, emphasising 
the need for further, well-designed randomised controlled trials to assess causality and 
the potential clinical benefits of vitamin D supplementation. In view of the costs and 
side-effects associated with antihypertensive drugs, the possibility of preventing or 
reducing hypertension with vitamin D supplementation is very attractive. However, 
because we cannot exclude the possibility that the findings from this study were caused 
by chance, they need to be replicated in an independent, similarly powered study.
Overall, our study provides genetic evidence that increased 25(OH)D concentrations are 
causally associated with reduced blood pressure and hypertension risk (panel). If replicated 
in an independent, similarly powered study, these findings will strengthen the case for 
appropriately powered, well-designed randomised clinical trials to investigate the necessary 
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vitamin D doses and appropriate target groups for the prevention or treatment of 
hypertension.
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Figure 1. Flow chart showing the sample sizes available at each stage of the meta-analyses
25(OH)D=25-hydroxyvitamin D. ICBP=International Consortium for Blood Pressure. 
CHARGE=Cohorts for Heart and Aging Research in Genomic Epidemiology. Global 
BPGen=Global Blood Pressure Genetics.
*Did not contribute data to analyses with the synthesis score single-nucleotide 
polymorphisms (SNPs) because of unavailability of the CYP3R3 SNP.
†Did not contribute data to analyses with the metabolism score SNPs because of 
unavailability of GC or CYP33A3 SNPs.
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Figure 2. Meta-analysis of D-CarDia studies with summary data from the ICBP, CHARGE, and 
Global BPGen consortia
Association of the synthesis score with systolic blood pressure, diastolic blood pressure, and 
hypertension. Includes data for 146 581 individuals, after exclusion of overlapping studies. 
The area of the grey boxes around a point estimate is proportional to the study’s weight in 
the meta-analysis. ICBP=International Consortium for Blood Pressure. CHARGE=Cohorts 
for Heart and Aging Research in Genomic Epidemiology. Global BPGen=Global Blood 
Pressure Genetics.
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Figure 3. Mendelian randomisation triangulation for hypertension
Instrumental variable ratio calculation done with the natural log of the odds (βZY). OR=odds 
ratio. 25(OH)D=25-hydroxyvitamin D.
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